While monoclonal antibodies and tyrosine kinase inhibitors represent major advances in the treatment of HER2-positive breast cancer, a significant number of patients with early breast cancer develop metastatic disease despite adjuvant systemic therapy. Here, ERBB2 is linked to breast cancer.